• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An agenda for future research projects in polycythemia vera and essential thrombocythemia.

作者信息

Barbui Tiziano, Vannucchi Alessandro Maria, Guglielmelli Paola, De Stefano Valerio, Rambaldi Alessandro

机构信息

FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo

Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera Universitaria Careggi and Department of Experimental and Clinical Medicine, University of Florence, Florence.

出版信息

Haematologica. 2020 Aug;105(8):1999-2003. doi: 10.3324/haematol.2019.246207. Epub 2020 May 28.

DOI:10.3324/haematol.2019.246207
PMID:32467140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7395271/
Abstract
摘要

相似文献

1
An agenda for future research projects in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症未来研究项目议程。
Haematologica. 2020 Aug;105(8):1999-2003. doi: 10.3324/haematol.2019.246207. Epub 2020 May 28.
2
The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.红细胞增多症或血小板增多症患者进展为真性红细胞增多症或原发性血小板增多症的发生率。
Ann Intern Med. 2003 Sep 16;139(6):470-5. doi: 10.7326/0003-4819-139-6-200309160-00009.
3
Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis.原发性血小板增多症与伴有显著血小板增多的真性红细胞增多症的鉴别。
Am J Hematol. 1987 Jun;25(2):191-201. doi: 10.1002/ajh.2830250209.
4
Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中的寡核苷酸阵列比较基因组杂交
Haematologica. 2008 Jul;93(7):1098-100. doi: 10.3324/haematol.12547.
5
Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化是1种、2种还是3种疾病？
Leukemia. 2021 Jul;35(7):1890-1893. doi: 10.1038/s41375-021-01254-w. Epub 2021 Apr 28.
6
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.与BCR/ABL阴性骨髓增殖性肿瘤（原发性血小板增多症和真性红细胞增多症）中的血小板增多症相比，BCR/ABL阳性血小板增多症在临床和骨髓特征方面的本质差异。
Acta Haematol. 2015;133(1):52-5. doi: 10.1159/000358915. Epub 2014 Aug 7.
7
[Essential thrombocythemia--a comparative study on polycythemia vera].
Rinsho Ketsueki. 1986 Mar;27(3):285-91.
8
Summaries for patients. Polycythemia vera and essential thrombocythemia in a general population.
Ann Intern Med. 2003 Sep 16;139(6):I32. doi: 10.7326/0003-4819-139-6-200309160-00002.
9
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.真性红细胞增多症/原发性血小板增多症后骨髓纤维化患者应用原发性骨髓纤维化预后评分的差异。
Haematologica. 2016 Oct;101(10):e405-e406. doi: 10.3324/haematol.2016.149013. Epub 2016 Jun 27.
10
Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.原发性血小板增多症和特发性骨髓纤维化中早期诊断的相关性：单中心经验。
Rev Clin Esp (Barc). 2022 Mar;222(3):169-173. doi: 10.1016/j.rceng.2021.07.003. Epub 2021 Oct 14.

引用本文的文献

1
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.血栓形成对真性红细胞增多症患者死亡和疾病进展概率的影响：1545 例患者的多状态转移分析。
Blood Cancer J. 2023 Dec 15;13(1):187. doi: 10.1038/s41408-023-00960-1.
2
Impact of Anti-Endothelial Cell Antibodies (AECAs) in Patients with Polycythemia Vera and Thrombosis.抗内皮细胞抗体（AECAs）对真性红细胞增多症和血栓形成患者的影响。
Diagnostics (Basel). 2022 Apr 25;12(5):1077. doi: 10.3390/diagnostics12051077.
3
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.原发性血小板增多症纤维化进展的临床和分子预测因素：一项涉及 1607 例患者的多中心研究。
Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6.

本文引用的文献

1
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.一项随机双盲试验，比较三种阿司匹林方案优化原发性血小板增多症的抗血小板治疗。
Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596.
2
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.验证 IPSET 评分在伴有前纤维化骨髓纤维化患者中的血栓形成风险。
Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2.
3
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.givinostat最大耐受剂量在真性红细胞增多症中的安全性和有效性：一项两部分的Ib/II期研究。
Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11.
4
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
5
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.芦可替尼预防真性红细胞增多症血栓形成：系统评价和荟萃分析。
Blood Adv. 2020 Jan 28;4(2):380-386. doi: 10.1182/bloodadvances.2019001158.
6
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.突变增强的原发性血小板增多症和真性红细胞增多症国际预后系统。
Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16.
7
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.内脏静脉血栓形成与骨髓增殖性肿瘤：一项国际性回顾性研究 518 例。
Am J Hematol. 2020 Feb;95(2):156-166. doi: 10.1002/ajh.25677. Epub 2019 Nov 29.
8
Oral idasanutlin in patients with polycythemia vera.口服伊达司他林治疗真性红细胞增多症。
Blood. 2019 Aug 8;134(6):525-533. doi: 10.1182/blood.2018893545. Epub 2019 Jun 5.
9
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.羟基脲和放血疗法对真性红细胞增多症患者预防动脉和静脉血栓形成的不同作用。
Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9.
10
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.羟基脲可预防骨髓增殖性肿瘤患者的动脉和晚期静脉血栓复发，但在脾静脉区无效。1500 例的汇总分析。
Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y.